Sonoma Pharmaceuticals (SNOA) Net Equity Issued and Repurchased (2011 - 2026)

Sonoma Pharmaceuticals' Net Equity Issued and Repurchased history runs 14 years deep, the most recent figure standing at $427000.0 for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $427000.0 in Q1 2026; TTM through Mar 2026 was $693000.0, a 63.16% decrease from a year earlier, with the FY2026 full-year figure at $427000.0, down 86.13% from the prior year.
• Net Equity Issued and Repurchased rose to $427000.0 in Q1 2026 per SNOA's latest filing, from $266000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $2.9 million in Q1 2023 and bottomed at -$5000.0 in Q2 2023.
• The 4-year median for Net Equity Issued and Repurchased is $427000.0 (2026), against an average of $776714.3.
• Biggest YoY gain for Net Equity Issued and Repurchased was 15060.0% in 2024; the steepest drop was 88.04% in 2024.
• Year by year, Net Equity Issued and Repurchased stood at -$5000.0 in 2023, then soared by 15900.0% to $790000.0 in 2024, then slumped by 66.33% to $266000.0 in 2025, then surged by 60.53% to $427000.0 in 2026.
• Per Business Quant, the three latest SNOA Net Equity Issued and Repurchased figures stand at $427000.0 (Q1 2026), $266000.0 (Q4 2025), and $790000.0 (Q4 2024).